Rucaparib was first indicated for the treatment of advanced ovarian cancer with either germline or somatic BRCA1/2 mutations, and was then approved in 2018 for the maintenance treatment of platinum‐sensitive ovarian, fallopian tubal, and peritoneal cancer regardless of the BRCA status.137. This evidence concerns the gene BRCA1 and ovarian carcinoma.